Michael A. Metzger - 13 Sep 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President and COO, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
13 Sep 2021
Net transactions value
-$726,833
Form type
4
Filing time
15 Sep 2021, 16:16:56 UTC
Next filing
22 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $119,887 +16,651 +94% $7.20 34,310 13 Sep 2021 Direct
transaction SNDX Common Stock Sale $316,639 -16,651 -49% $19.02 17,659 13 Sep 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $319,313 +44,349 +251% $7.20 62,008 14 Sep 2021 Direct
transaction SNDX Common Stock Sale $849,394 -44,349 -72% $19.15 17,659 14 Sep 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -16,651 -100% $0.000000* 0 13 Sep 2021 Common Stock 16,651 $7.20 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -44,349 -100% $0.000000* 0 14 Sep 2021 Common Stock 44,349 $7.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.
F2 The sale prices ranged from $19.00 to $19.10
F3 The sale prices ranged from $19.00 to $19.31
F4 This option is fully vested.